Fig. 1
From: Blocking interleukin-23 ameliorates neuromuscular and thymic defects in myasthenia gravis
Effects of anti-IL-23p19 treatment on clinical manifestations in EAMG model. Weekly analysis of the global clinical score in EAMG mice (A) and area under the curve for the global clinical score (B). Analysis of CMAP following 10 stimulations (C), the specific maximal force (D) and relaxation time (E) in the tibialis anterior muscles of EAMG mice were performed at the killing time after 4 weeks of treatment. Data for EAMG (n > 12 per group) mice were obtained from 4 independent experiments. P values were obtained with ANOVA test. The P values are indicated as follows: * < 0.05; ** < 0.008; **** < 0.0001